Table 3.
Genome-wide association study (GWAS) results by study sample and combined in meta-analysis: Vasomotor symptoms ever vs. nevera
| GARNET Study | SHARe - AA Study | SHARe - HA Study | WHIMS+ Study | Meta-analysis p-value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Refsnp IDb | CHR:POSc | OR (SE) | p-value | OR (SE) | p-value | OR (SE) | p-value | OR (SE) | p-value | |
| rs74827081 | 4:104556732 | 1.65 (0.18) | 7.88e-6 | 1.83(0. 34) | 1.25e-3 | 1.64 (0.24) | 7.46e-4 | 1.54 (0.15) | 6.41e-6 | 4.77e-15 |
| rs74589515 | 4:104584258 | 1.60 (0.18) | 2.71e-5 | 1.80 (0.32) | 1.11e-3 | 1.61 (0.23) | 9.62e-4 | 1.57 (0.15) | 2.92e-6 | 7.11e-15 |
| rs79246187 | 4:104580809 | 1.61 (0.18) | 2.1e-5 | 1.51 (0.23) | 7.46e-3 | 1.60 (0.23) | 1.02e-3 | 1.57 (0.15) | 2.63e-6 | 2.64e-14 |
| rs112390256 | 4:104575473 | 1.64 (0.18) | 9.46e-6 | 1.51 (0.24) | 8.92e-3 | 1.61 (0.23) | 9.87e-4 | 1.54 (0.15) | 4.97e-6 | 2.81e-14 |
| rs75544266 | 4:104584997 | 1.60 (0.18) | 2.84e-5 | 1.51 (0.23) | 6.55e-3 | 1.60 (0.23) | 9.42e-4 | 1.57 (0.15) | 2.89e-6 | 3.15e-14 |
| rs78154848 | 4:104562840 | 1.65 (0.18) | 8.16e-6 | 1.46 (0.24) | 1.94e-2 | 1.62 (0.24) | 8.61e-4 | 1.54 (0.15) | 6.05e-6 | 5.65e-14 |
| rs76643670 | 4:104562842 | 1.65 (0.18) | 8.16e-6 | 1.46 (0.24) | 1.94e-2 | 1.62 (0.24) | 8.59e-4 | 1.54 (0.15) | 6.05e-6 | 5.65e-14 |
| rs78289784 | 4:104580155 | 1.61 (0.18) | 2.12e-5 | 1.46 (0.23) | 1.51e-2 | 1.60 (0.23) | 9.92e-4 | 1.56 (0.15) | 3.28e-6 | 6.55e-14 |
| rs77322567 | 4:104569676 | 1.64 (0.18) | 8.62e-6 | 1.23 (0.13) | 5.12e-2 | 1.55 (0.22) | 2.24e-3 | 1.53 (0.15) | 6.52e-6 | 2.17e-12 |
| rs78141901 | 4:104593977 | 1.42 (0.16) | 2.67e-3 | 1.80 (0.37) | 3.88e-3 | 1.35 (0.23) | 7.62e-2 | 1.55 (0.16) | 1.31e-5 | 7.27e-10 |
| rs78844131 | 4:104600029 | 1.41 (0.16) | 2.85e-3 | 1.49 (0.26) | 2.08e-2 | 1.30 (0.22) | 1.17e-1 | 1.56 (0.16) | 1.14e-5 | 3.34e-09 |
| rs79852843 | 4:104628587 | 1.44 (0.17) | 1.68e-3 | 1.49 (0.29) | 4.45e-2 | 1.22 (0.20) | 2.22e-1 | 1.58 (0.16) | 5.08e-6 | 4.38e-09 |
| rs80328778 | 4:104612447 | 1.42 (0.16) | 2.15e-3 | 1.46 (0.27) | 3.67e-2 | 1.24 (0.21) | 1.95e-1 | 1.57 (0.16) | 7.06e-6 | 4.97e-09 |
| rs112623956 | 4:104623714 | 1.42 (0.16) | 2.33e-3 | 1.49 (0.27) | 2.83e-2 | 1.20 (0.20) | 2.67e-1 | 1.57 (0.16) | 6.19e-6 | 6.19e-09 |
| rs75699757 | 11:56818268 | 1.08 (0.08) | 3.01e-01 | 1.98 (0.24) | 1.16e-08 | 0.84 (0.10) | 1.16e-01 | 0.86 (0.05) | 1.51e-02 | 7.07e-01 |
| rs11518608 | 11:56767184 | 1.07 (0.08) | 3.67e-01 | 1.91 (0.22) | 3.47e-08 | 0.87 (0.10) | 2.13e-01 | 0.91 (0.06) | 1.09e-01 | 3.80e-01 |
| rs148680409 | 3:173330544 | Missing | Missing | 7.47 (2.73) | 3.69e-08 | 2.90 (3.33) | 3.54e-01 | Missing | Missing | Missing |
Table displays the results that were statistically significant (p-value threshold <5x10-8) in the meta-analysis of data from all 3 GWAS studies and/or in the individual studies. Odds ratio (OR) is expressed as allelic OR (standard error). Reference group is “never had vasomotor symptoms”. Adjusted for bilateral oophorectomy, age, smoking, alcohol intake, physical activity, population structure, body mass index, education, income, and menopausal estrogen therapy use. GARNET Study denotes the Genome-wide Association Studies of Treatment Response in Randomized Clinical Trials cohort of women of non-Hispanic European ancestry. SHARe-AA Study denotes the SNP Health Association Resource cohort African American women. SHARe-HA Study denotes the SNP Health Association Resource cohort Hispanic American women. WHIMS+ Study denotes the Women’s Health Initiative Memory Study cohort of women of non-Hispanic European ancestry.
Refsnp identification numbers (IDs) were obtained from the SNP locations for Homo sapiens (dbSNP Build 144) Bioconductor package.
CHR:POS denotes chromosome assignment and position of SNP according to Build 37.